Background: There are limited epidemiologic data on cerebral venous sinus thrombosis (CVST). We aim to summarize baseline characteristics and outcomes using a large nationally representative administrative database. Methods: Using the 2013 Nationwide Readmissions Database, we used validated International Classification of Disease, Ninth Revision codes to identify baseline characteristics of patients admitted with CVST. We calculated readmission rates (per 100,000 index hospitalizations) for neurological complications. Multivariable Poisson regression yielded rate ratios (RR) of associations between index admission variables and all-cause readmission up to 1 year. Results: Among 2,105 patients with index admission for CVST, mean age was 46.8 (SD 18.4); 65.2% were female, and 6.1% were pregnant. Hemorrhagic stroke (15.6%) was more common than ischemic stroke (10.7%), seizure occurred in 16.3, and 3.7% of patients died during index hospitalization. The 90-day readmission rate (per 100,000 index CVST hospitalizations) was the highest for CVST (1,447) and ischemic stroke (755). Diabetes (RR 1.10, 95% CI 1.002–1.22), cancer (1.23, 1.09–1.39), insurance status (0.92, 0.83–0.97 for Medicare/private insurance vs. others), and discharge home (RR 0.89, 95% CI 0.85–0.99) were associated with increased readmission rate. Conclusions: We provide baseline characteristics and readmission rates after CVST over a 1-year period. In-hospital mortality rate and association with pregnancy were lower than previously observed.

Keywords:
Cerebral venous thrombosis, All cerebrovascular disease/stroke, Risk factors in epidemiology, Cohort studies, All epidemiology
1.
Ferro JM, Correia M, Pontes C, Baptista MV, Pita F; Cerebral Venous Thrombosis Portuguese Collaborative Study Group (Venoport): Cerebral vein and dural sinus thrombosis in Portugal: 1980–1998. Cerebrovasc Dis 2001; 11: 177–182.
2.
Coutinho JM, Zuurbier SM, Aramideh M, Stam J: The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke 2012; 43: 3375–3377.
3.
Borhani Haghighi A, Edgell RC, Cruz-Flores S, et al: Mortality of cerebral venous-sinus thrombosis in a large national sample. Stroke 2012; 43: 262–264.
4.
Duman T, Uluduz D, Midi I, et al: A multicenter study of 1144 patients with cerebral venous thrombosis: the VENOST study. J Stroke Cerebrovasc Dis 2017; 26: 1848–1857.
5.
Korathanakhun P, Sathirapanya P, Geater SL, Petpichetchian W: Predictors of hospital outcome in patients with cerebral venous thrombosis. J Stroke Cerebrovasc Dis 2014; 23: 2725–2729.
6.
Idris MN, Sokrab TE, Ibrahim EA, et al: Cerebral venous thrombosis. Clinical presentation and outcome in a prospective series from Sudan. Neurosciences (Riyadh) 2008; 13: 408–411.
7.
Shindo A, Wada H, Ishikawa H, et al: Clinical features and underlying causes of cerebral venous thrombosis in Japanese patients. Int J Hematol 2014; 99: 437–440.
8.
Khealani BA, Wasay M, Saadah M, et al: Cerebral venous thrombosis: a descriptive multicenter study of patients in Pakistan and middle east. Stroke 2008; 39: 2707–2711.
9.
Zuluaga MI, Massaro M, Franco CA: [Cerebral venous sinus thrombosis: epidemiology, clinical characteristics, imaging and prognosis]. Biomedica 2015; 35: 196–203.
10.
Wang B, Peng C, Zhou MK, Guo J, He L: [Clinical characteristics and prognosis of patients with cerebral venous sinus thrombosis in southwest China]. Sichuan Da Xue Xue Bao Yi Xue Ban 2014; 45: 515–518.
11.
Wang JW, Li JP, Song YL, et al: Clinical characteristics of cerebral venous sinus thrombosis. Neurosciences (Riyadh) 2015; 20: 292–295.
12.
Terazzi E, Mittino D, Rudà R, et al: Cerebral venous thrombosis: a retrospective multicentre study of 48 patients. Neurol Sci 2005; 25: 311–315.
13.
Ruiz-Sandoval JL, Chiquete E, Bañuelos-Becerra LJ, et al: Cerebral venous thrombosis in a Mexican multicenter registry of acute cerebrovascular disease: the RENAMEVASC study. J Stroke Cerebrovasc Dis 2012; 21: 395–400.
14.
de Bruijn SF, de Haan RJ, Stam J: Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients. For the cerebral venous sinus thrombosis study group. J Neurol Neurosurg Psychiatry 2001; 70: 105–108.
15.
Breteau G, Mounier-Vehier F, Godefroy O, et al: Cerebral venous thrombosis 3-year clinical outcome in 55 consecutive patients. J Neurol 2003; 250: 29–35.
16.
Preter M, Tzourio C, Ameri A, Bousser MG: Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients. Stroke 1996; 27: 243–246.
17.
Liberman AL, Kamel H, Mullen MT, Messé SR: International classification of diseases, ninth revision (ICD-9) diagnosis codes can identify cerebral venous thrombosis in hospitalized adults. Neurohospitalist 2016; 6: 147–150.
18.
Thigpen JL, Dillon C, Forster KB, et al: Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. Circ Cardiovasc Qual Outcomes 2015; 8: 8–14.
19.
Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF: Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005; 43: 480–485.
20.
Wiley LK, Shah A, Xu H, Bush WS: ICD-9 tobacco use codes are effective identifiers of smoking status. J Am Med Inform Assoc 2013; 20: 652–658.
21.
Kee VR, Gilchrist B, Granner MA, Sarrazin NR, Carnahan RM: A systematic review of validated methods for identifying seizures, convulsions, or epilepsy using administrative and claims data. Pharmacoepidemiol Drug Saf 2012; 21(suppl 1): 183–193.
22.
Tamariz L, Harkins T, Nair V: A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf 2012; 21(suppl 1): 154–162.
23.
Fong A, Chau CT, Pan D, Ogunyemi DA: Clinical morbidities, trends, and demographics of eclampsia: a population-based study. Am J Obstet Gynecol 2013; 209: 229.
24.
Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators: Prognosis of cerebral vein and dural sinus thrombosis: results of the international study on cerebral vein and dural sinus thrombosis (ISCVT). Stroke 2004; 35: 664–670.
25.
Kumral E, Polat F, Uzunköprü C, Callı C, Kitiş Ö: The clinical spectrum of intracerebral hematoma, hemorrhagic infarct, non-hemorrhagic infarct, and non-lesional venous stroke in patients with cerebral sinus-venous thrombosis. Eur J Neurol 2012; 19: 537–543.
26.
Wasay M, Bakshi R, Bobustuc G, et al: Cerebral venous thrombosis: analysis of a multicenter cohort from the United States. J Stroke Cerebrovasc Dis 2008; 17: 49–54.
27.
Ferro JM, Lopes MG, Rosas MJ, Ferro MA, Fontes J; Cerebral Venous Thrombosis Portugese Collaborative Study Group: Long-term prognosis of cerebral vein and dural sinus thrombosis. results of the VENOPORT study. Cerebrovasc Dis 2002; 13: 272–278.
28.
Maali L, Khan S, Qeadan F, Ismail M, Ramaswamy D, Hedna VS: Cerebral venous thrombosis: continental disparities. Neurol Sci 2017; 38: 1963–1968.
29.
Dentali F, Poli D, Scoditti U, et al: Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost 2012; 10: 1297–1302.
30.
Topaz M, Shafran-Topaz L, Bowles KH: ICD-9 to ICD-10: evolution, revolution, and current debates in the United States. Perspect Health Inf Manag 2013; 10: 1d.
31.
Quan H, Li B, Saunders LD, et al: Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res 2008; 43: 1424–1441.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.